Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market is the research report that tells you how to obtain orphan drug status for products in Asian countries and the benefits that go along with it. This invaluable guide to Asia reviews orphan drug regulations across the continent and discusses crucial business issues unique to that part of the world.
You’ll get a country-by-country breakdown of:
All this and more from Ames Gross and John Minot of Pacific Bridge Medical, the consulting firm that has provided more than 200 companies with regulatory information and business strategies to develop Asian markets.
This research report provides exhaustive coverage of the regulatory and business environments in:
This guide also offers insight into the global outlook for rare diseases, an overview of the Asian economy and an analysis of the pharmaceutical market. In addition, it includes advice on how to do business after getting orphan drug status, with sections on preparing sales forecasts, what kind of support is available in Asian countries and distribution strategies. Plus, included is a list of orphan drugs currently on the market in Asia and a directory of orphan drug associations active in the region.
Click here to view a sample page of this report.
Take advantage of the opportunities available for your products in Asia with Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market. Priced at $1,500 (including shipping) and available to you today.
Need your copy in a rush? You may receive your order express delivery for an additional $50. International express delivery takes two days. In the U.S., your order will be shipped for overnight delivery.
Your purchase is nonrefundable. All sales are final.